Tagged with clinic

Belgium Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the increasing trend of personalized medicine, digitalization, big healthcare data, and stakeholder partnerships. Additionally, Van De Sompel also elaborates on Pfizer’s…

Czech Republic Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning itself as the one-stop-shop for both the clinical and analytical aspects of clinical research. He also explains how Quinta Analytica…

Belgium Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as creating value-based agreements for reimbursements, (clinical) research and development, and embracing the opportunities of patient data. Dreno also discusses her…

Belgium Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.  …

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Morocco Sanaa Sayagh of Roche Morocco shares her commitment to bringing the latest immunotherapies to Moroccan patients through partnerships with health authorities and the Lalla Salma Foundation on creative access programs. Sayagh also touches on how Roche is attempting to make personalised healthcare a reality in Morocco.   Despite the lack…

Czech Republic Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of the Czech clinical research landscape and its challenges and opportunities.   Without any doubt, my biggest achievement at EastHORN is…

Czech Republic The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical trials. However, a decline in the number of clinical trials in recent years means that Czech stakeholders are looking to…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Czech Republic Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many continue to capitalize on the country’s universal healthcare system. Vaculík also shares his views on how to retain a strong…